<DOC>
	<DOCNO>NCT02281279</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose romidepsin lenalidomide combine rituximab see well combination work treat patient B-cell non-Hodgkin lymphoma return ( recurrent ) respond treatment ( refractory ) . Monoclonal antibody , rituximab , may block cancer growth different way target certain cell . Romidepsin lenalidomide may stop growth cancer cell block enzymes need cell growth . Giving rituximab together romidepsin lenalidomide may better treatment B-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Rituximab , Romidepsin , Lenalidomide Treating Patients With Recurrent Refractory B-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish maximum tolerate dose ( MTD ) combination romidepsin , rituximab lenalidomide patient relapsed/refractory B-cell non-Hodgkin lymphoma ( NHL ) . ( Phase I ) II . To assess overall response rate ( ORR ) combination patient transform follicular lymphoma ( FL ) . ( Phase II ) SECONDARY OBJECTIVES : I . To assess toxicity safety romidepsin combination lenalidomide rituximab . II . To assess complete response rate ( CR ) , progression free survival ( PFS ) , overall survival ( OS ) combination patient transform FL . TERTIARY OBJECTIVES : I . To assess impact B-cell leukemia/lymphoma 2 ( BCL2 ) mutation ORR among patient treat combination . II . To assess impact BCL2 mutation PFS among patient treat combination . OUTLINE : This phase I , dose-escalation study romidepsin lenalidomide follow phase II study . Patients receive rituximab intravenously ( IV ) 90 minute day 1 ; romidepsin IV 4 hour either day 1 , day 1 8 , day 1 , 8 , 15 ; lenalidomide orally ( PO ) day 1-21 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>PHASE I : Histological confirmation relapse ( recurrent previous therapy [ y ] ) refractory ( response previous therapy [ y ] ) Bcell NHL ; note : patient small lymphocytic lymphoma ( SLL ) eligible however patient chronic lymphocytic leukemia ( CLL ) eligible PHASE II : Histological confirmation transformation FL lymphoma diffuse large B cell lymphoma aggressive lymphoma The biopsy confirm diagnosis 12 week prior registration long intervening therapy ; note : patient lymphoma treatment since previous biopsy , biopsy repeat Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Measurable disease ( least 1 lesion &gt; = 1.5 cm diameter ) detect compute tomography ( CT ) CT image positron emission tomography ( PET ) /CT Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 75,000/mm^3 Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) total bilirubin &gt; 1.5 x ULN , direct bilirubin = &lt; ULN Alkaline phosphatase = &lt; 3 x ULN unless due direct lymphoma involvement , = &lt; 5 x ULN Aspartate transaminase ( AST ) = &lt; 3 x ULN unless due direct lymphoma involvement , = &lt; 5x ULN Calculated creatinine clearance &gt; = 50 mL/min use CockcroftGault formula Magnesium &gt; = 1.6 mg/dL Potassium &gt; = 3.5 mg/dL Females reproductive potential must adhere scheduled pregnancy test require Revlimid Risk Evaluation Mitigation Strategy ( REMS ) ® program Willing register mandatory Revlimid REMS® program , willing able comply requirement REMS® program If currently anticoagulation medication , willing able take aspirin ( 325 mg ) daily ; note : aspirin contraindicate , patient may consider study therapeutic dose warfarin low molecular weight heparin ; patient unable take prophylaxis eligible Life expectancy &gt; = 3 month Ability complete medication diary assistance Ability provide inform write consent Willing return enrol institution followup ( active monitoring phase study ) Note : active monitoring phase study ( i.e. , active treatment observation ) , participant must willing return consent institution followup Willing provide tissue central review blood sample correlative research purpose Prior therapy histone deacetylase ( HDAC ) inhibitor immunomodulatory drug ( IMDs ) ( lenalidomide thalidomide ) Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Active central nervous system ( CNS ) lymphoma cerebrospinal fluid involvement malignant lymphoma cell require therapy Prolongation correct QT interval &gt; 480 m Receiving medication prolong correct QT ( QTc ) know risk Torsades de pointes ; note : provider use caution drug possible increase risk Torsades de pointes ; patient eligible take medication prior initiation therapy le 4 halflife medication Receiving medication substance strong inhibitor cytochrome P450 , family 3 , subfamily A , polypeptide 4/5 ( CYP3A4/5 ) Use follow strong inhibitor prohibit = &lt; 7 day prior registration Boceprevir ( Victrelis™ ) Clarithromycin ( Biaxin® , Biaxin XL® ) Conivaptan ( Vaprisol® ) Grapefruit juice Indinavir ( Crixivan® ) Itraconazole ( Sporanox® ) Ketoconazole ( Nizoral® ) Lopinavir/ritonavir ( Kaletra® ) Mibefradil Nefazodone ( Serzone® ) Nelfinavir ( Viracept® ) Posaconazole ( Noxafil® ) Ritonavir ( Norvir® ) Saquinavir ( Invirase® ) Telaprevir ( Incivek® ) Telithromycin ( Ketek® ) Receiving medication substance inducer CYP3A4 Use follow inducer prohibit = &lt; 12 day prior registration Avasimibe Bosentan ( Tracleer® ) Carbamazepine ( Carbatrol® , Epitol® , Equetro™ , Tegretol® , TegretolXR® ) Efavirenz ( Sustiva® ) Modafinil ( Provigil® ) Phenobarbital ( Luminal® ) Phenytoin ( Dilantin® , Phenytek® ) Rifabutin ( Mycobutin® ) Rifampin ( Rifadin® ) St. John 's wort Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Known positivity human immunodeficiency virus ( HIV ) ; note : baseline test HIV require Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; note : patient hepatitis B C eligible discretion treat physician ; appropriate counseling regard risk rituximab provide Receiving investigational agent would consider treatment primary neoplasm Other active malignancy require therapy ; exception : nonmelanotic skin cancer cancer judgment investigator interfere treatment plan response assessment ; patient &gt; = 25 % bone marrow radiate disease eligible History myocardial infarction = &lt; 6 month prior registration , unstable angina , congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia History life threaten recurrent thrombosis/embolism ; patient may participate anticoagulation treatment Receiving erythroid stimulating agent ( erythropoietin [ EPO ] : Procrit , Aranesp ) History allogeneic bone marrow stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>